A robust organoid-based platform for high-throughput screening and drug discovery

Patient-derived organoids (PDOs), or HUB Organoids®, are advanced 3D models generated from adult stem cells of normal and malignant epithelial tissues and stored in high-quality biobanks to ensure reproducibility. HUB Organoids faithfully recapitulate the physiology, molecular heterogeneity, and morphological and functional characteristics of the original tissue, effectively mimicking patient response and bridging the gap between laboratory research and clinical application-bringing the “patient into the lab.” The rapid development of Petosemtamab (MCLA-158) exemplifies the value of organoid technology in drug development, as this target could not have been identified using conventional 2D models. Further supporting this, recent publications highlight the ability of organoids to predict treatment response in metastatic colorectal cancer. Here, we present our capabilities for medium- to high-throughput screening, enabling the evaluation of over 6,000 compounds across multiple organoid models in parallel. Available readouts include plate reader-based viability assays (CellTiter-Glo 3D) and imaging-based assays (CyQuant). Beyond initial large-scale screening, rapid iterations of follow-up structure-activity relationship (SAR) studies or expanded screening across diverse patient models are facilitated by the precision and reproducibility of our platform. In summary, we offer a robust, clinically relevant, and cost-effective platform to support drug development from early-stage compound screening to advanced validation studies.